Role of Fecal Microbiota Transplantation in Managing Clostridium Difficile Infection and Inflammatory Bowel Disease: A Narrative Review
Fecal microbiota transplantation (FMT) has been emerging as an alternate treatment modality in the management of patients with dysbiosis by restoring abnormal gut microbiota composition through the transplantation of normal fecal microbiota from healthy donors. This technique has lately gained a lot...
Gespeichert in:
| Veröffentlicht in: | Curēus (Palo Alto, CA) CA), 2023-12, Vol.15 (12), p.e51004 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 12 |
| container_start_page | e51004 |
| container_title | Curēus (Palo Alto, CA) |
| container_volume | 15 |
| creator | Ghazanfar, Haider Kandhi, Sameer Acherjee, Trishna Qureshi, Zaheer A Shaban, Mohammed Yordanka, Diaz Saez Cordero, Dessiree Chinta, Siddarth Jyala, Abhilasha Patel, Harish |
| description | Fecal microbiota transplantation (FMT) has been emerging as an alternate treatment modality in the management of patients with dysbiosis by restoring abnormal gut microbiota composition through the transplantation of normal fecal microbiota from healthy donors. This technique has lately gained a lot of attention in the treatment of recurrent or refractory
infection (CDI) owing to its high success rates combined with its favorable safety profile. FMT has also been attracting the interest of clinicians as a new treatment option for inflammatory bowel diseases (IBD). Here, we reviewed most of the recent advancements in the use of FMT for CDI as well as its use in the treatment of IBD. |
| doi_str_mv | 10.7759/cureus.51004 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10802990</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2917863403</sourcerecordid><originalsourceid>FETCH-LOGICAL-c300t-1612c707661e19a9f7136e1fdc455e806ad82b2a601bd75536b1c15ab446a4eb3</originalsourceid><addsrcrecordid>eNpdkcFu1DAQhiMEolXpjTOyxIUDW8ZOYjtcUFkoVGpBqsrZmjiTxVViL3ayVZ-gr11vt1SFk8eaT59m5i-K1xyOlKqbD3aONKejmgNUz4p9waVeaK6r50_qveIwpSsA4KAEKHhZ7JVa1E2pm_3i9iIMxELPTsjiwM6djaF1YUJ2GdGn9YB-wskFz5xn5-hx5fyKLYeQpug6N4_si-t7Z122nPqe7D2Lvtv-BhxHnEK8YZ_DNQ0ZTYSJPrJj9gNjzN4NsQvaOLp-VbzocUh0-PAeFL9Ovl4uvy_Ofn47XR6fLWwJMC245MIqUFJy4g02veKlJN53tqpr0iCx06IVKIG3narrUrbc8hrbqpJYUVseFJ923vXcjtRZ8lPEwayjGzHemIDO_Nvx7rdZhY3hoEE0DWTDuwdDDH9mSpMZXbI05EtRmJMRDVdalhWUGX37H3oV5ujzfpkSIKHRYku931H59ClF6h-n4WC2KZtdyuY-5Yy_ebrBI_w30_IONDqljQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2920609823</pqid></control><display><type>article</type><title>Role of Fecal Microbiota Transplantation in Managing Clostridium Difficile Infection and Inflammatory Bowel Disease: A Narrative Review</title><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Ghazanfar, Haider ; Kandhi, Sameer ; Acherjee, Trishna ; Qureshi, Zaheer A ; Shaban, Mohammed ; Yordanka, Diaz Saez ; Cordero, Dessiree ; Chinta, Siddarth ; Jyala, Abhilasha ; Patel, Harish</creator><creatorcontrib>Ghazanfar, Haider ; Kandhi, Sameer ; Acherjee, Trishna ; Qureshi, Zaheer A ; Shaban, Mohammed ; Yordanka, Diaz Saez ; Cordero, Dessiree ; Chinta, Siddarth ; Jyala, Abhilasha ; Patel, Harish</creatorcontrib><description>Fecal microbiota transplantation (FMT) has been emerging as an alternate treatment modality in the management of patients with dysbiosis by restoring abnormal gut microbiota composition through the transplantation of normal fecal microbiota from healthy donors. This technique has lately gained a lot of attention in the treatment of recurrent or refractory
infection (CDI) owing to its high success rates combined with its favorable safety profile. FMT has also been attracting the interest of clinicians as a new treatment option for inflammatory bowel diseases (IBD). Here, we reviewed most of the recent advancements in the use of FMT for CDI as well as its use in the treatment of IBD.</description><identifier>ISSN: 2168-8184</identifier><identifier>EISSN: 2168-8184</identifier><identifier>DOI: 10.7759/cureus.51004</identifier><identifier>PMID: 38259389</identifier><language>eng</language><publisher>United States: Cureus Inc</publisher><subject>Antibiotics ; Bacteria ; Colon ; Colonoscopy ; Endoscopy ; Feces ; Gastroenterology ; Infections ; Inflammation ; Inflammatory bowel disease ; Microbiota ; Ostomy ; Patients</subject><ispartof>Curēus (Palo Alto, CA), 2023-12, Vol.15 (12), p.e51004</ispartof><rights>Copyright © 2023, Ghazanfar et al.</rights><rights>Copyright © 2023, Ghazanfar et al. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2023, Ghazanfar et al. 2023 Ghazanfar et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c300t-1612c707661e19a9f7136e1fdc455e806ad82b2a601bd75536b1c15ab446a4eb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10802990/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10802990/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38259389$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ghazanfar, Haider</creatorcontrib><creatorcontrib>Kandhi, Sameer</creatorcontrib><creatorcontrib>Acherjee, Trishna</creatorcontrib><creatorcontrib>Qureshi, Zaheer A</creatorcontrib><creatorcontrib>Shaban, Mohammed</creatorcontrib><creatorcontrib>Yordanka, Diaz Saez</creatorcontrib><creatorcontrib>Cordero, Dessiree</creatorcontrib><creatorcontrib>Chinta, Siddarth</creatorcontrib><creatorcontrib>Jyala, Abhilasha</creatorcontrib><creatorcontrib>Patel, Harish</creatorcontrib><title>Role of Fecal Microbiota Transplantation in Managing Clostridium Difficile Infection and Inflammatory Bowel Disease: A Narrative Review</title><title>Curēus (Palo Alto, CA)</title><addtitle>Cureus</addtitle><description>Fecal microbiota transplantation (FMT) has been emerging as an alternate treatment modality in the management of patients with dysbiosis by restoring abnormal gut microbiota composition through the transplantation of normal fecal microbiota from healthy donors. This technique has lately gained a lot of attention in the treatment of recurrent or refractory
infection (CDI) owing to its high success rates combined with its favorable safety profile. FMT has also been attracting the interest of clinicians as a new treatment option for inflammatory bowel diseases (IBD). Here, we reviewed most of the recent advancements in the use of FMT for CDI as well as its use in the treatment of IBD.</description><subject>Antibiotics</subject><subject>Bacteria</subject><subject>Colon</subject><subject>Colonoscopy</subject><subject>Endoscopy</subject><subject>Feces</subject><subject>Gastroenterology</subject><subject>Infections</subject><subject>Inflammation</subject><subject>Inflammatory bowel disease</subject><subject>Microbiota</subject><subject>Ostomy</subject><subject>Patients</subject><issn>2168-8184</issn><issn>2168-8184</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNpdkcFu1DAQhiMEolXpjTOyxIUDW8ZOYjtcUFkoVGpBqsrZmjiTxVViL3ayVZ-gr11vt1SFk8eaT59m5i-K1xyOlKqbD3aONKejmgNUz4p9waVeaK6r50_qveIwpSsA4KAEKHhZ7JVa1E2pm_3i9iIMxELPTsjiwM6djaF1YUJ2GdGn9YB-wskFz5xn5-hx5fyKLYeQpug6N4_si-t7Z122nPqe7D2Lvtv-BhxHnEK8YZ_DNQ0ZTYSJPrJj9gNjzN4NsQvaOLp-VbzocUh0-PAeFL9Ovl4uvy_Ofn47XR6fLWwJMC245MIqUFJy4g02veKlJN53tqpr0iCx06IVKIG3narrUrbc8hrbqpJYUVseFJ923vXcjtRZ8lPEwayjGzHemIDO_Nvx7rdZhY3hoEE0DWTDuwdDDH9mSpMZXbI05EtRmJMRDVdalhWUGX37H3oV5ujzfpkSIKHRYku931H59ClF6h-n4WC2KZtdyuY-5Yy_ebrBI_w30_IONDqljQ</recordid><startdate>20231223</startdate><enddate>20231223</enddate><creator>Ghazanfar, Haider</creator><creator>Kandhi, Sameer</creator><creator>Acherjee, Trishna</creator><creator>Qureshi, Zaheer A</creator><creator>Shaban, Mohammed</creator><creator>Yordanka, Diaz Saez</creator><creator>Cordero, Dessiree</creator><creator>Chinta, Siddarth</creator><creator>Jyala, Abhilasha</creator><creator>Patel, Harish</creator><general>Cureus Inc</general><general>Cureus</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20231223</creationdate><title>Role of Fecal Microbiota Transplantation in Managing Clostridium Difficile Infection and Inflammatory Bowel Disease: A Narrative Review</title><author>Ghazanfar, Haider ; Kandhi, Sameer ; Acherjee, Trishna ; Qureshi, Zaheer A ; Shaban, Mohammed ; Yordanka, Diaz Saez ; Cordero, Dessiree ; Chinta, Siddarth ; Jyala, Abhilasha ; Patel, Harish</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c300t-1612c707661e19a9f7136e1fdc455e806ad82b2a601bd75536b1c15ab446a4eb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antibiotics</topic><topic>Bacteria</topic><topic>Colon</topic><topic>Colonoscopy</topic><topic>Endoscopy</topic><topic>Feces</topic><topic>Gastroenterology</topic><topic>Infections</topic><topic>Inflammation</topic><topic>Inflammatory bowel disease</topic><topic>Microbiota</topic><topic>Ostomy</topic><topic>Patients</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ghazanfar, Haider</creatorcontrib><creatorcontrib>Kandhi, Sameer</creatorcontrib><creatorcontrib>Acherjee, Trishna</creatorcontrib><creatorcontrib>Qureshi, Zaheer A</creatorcontrib><creatorcontrib>Shaban, Mohammed</creatorcontrib><creatorcontrib>Yordanka, Diaz Saez</creatorcontrib><creatorcontrib>Cordero, Dessiree</creatorcontrib><creatorcontrib>Chinta, Siddarth</creatorcontrib><creatorcontrib>Jyala, Abhilasha</creatorcontrib><creatorcontrib>Patel, Harish</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Curēus (Palo Alto, CA)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ghazanfar, Haider</au><au>Kandhi, Sameer</au><au>Acherjee, Trishna</au><au>Qureshi, Zaheer A</au><au>Shaban, Mohammed</au><au>Yordanka, Diaz Saez</au><au>Cordero, Dessiree</au><au>Chinta, Siddarth</au><au>Jyala, Abhilasha</au><au>Patel, Harish</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Role of Fecal Microbiota Transplantation in Managing Clostridium Difficile Infection and Inflammatory Bowel Disease: A Narrative Review</atitle><jtitle>Curēus (Palo Alto, CA)</jtitle><addtitle>Cureus</addtitle><date>2023-12-23</date><risdate>2023</risdate><volume>15</volume><issue>12</issue><spage>e51004</spage><pages>e51004-</pages><issn>2168-8184</issn><eissn>2168-8184</eissn><abstract>Fecal microbiota transplantation (FMT) has been emerging as an alternate treatment modality in the management of patients with dysbiosis by restoring abnormal gut microbiota composition through the transplantation of normal fecal microbiota from healthy donors. This technique has lately gained a lot of attention in the treatment of recurrent or refractory
infection (CDI) owing to its high success rates combined with its favorable safety profile. FMT has also been attracting the interest of clinicians as a new treatment option for inflammatory bowel diseases (IBD). Here, we reviewed most of the recent advancements in the use of FMT for CDI as well as its use in the treatment of IBD.</abstract><cop>United States</cop><pub>Cureus Inc</pub><pmid>38259389</pmid><doi>10.7759/cureus.51004</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2168-8184 |
| ispartof | Curēus (Palo Alto, CA), 2023-12, Vol.15 (12), p.e51004 |
| issn | 2168-8184 2168-8184 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10802990 |
| source | PubMed Central; PubMed Central Open Access |
| subjects | Antibiotics Bacteria Colon Colonoscopy Endoscopy Feces Gastroenterology Infections Inflammation Inflammatory bowel disease Microbiota Ostomy Patients |
| title | Role of Fecal Microbiota Transplantation in Managing Clostridium Difficile Infection and Inflammatory Bowel Disease: A Narrative Review |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T02%3A45%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Role%20of%20Fecal%20Microbiota%20Transplantation%20in%20Managing%20Clostridium%20Difficile%20Infection%20and%20Inflammatory%20Bowel%20Disease:%20A%20Narrative%20Review&rft.jtitle=Cur%C4%93us%20(Palo%20Alto,%20CA)&rft.au=Ghazanfar,%20Haider&rft.date=2023-12-23&rft.volume=15&rft.issue=12&rft.spage=e51004&rft.pages=e51004-&rft.issn=2168-8184&rft.eissn=2168-8184&rft_id=info:doi/10.7759/cureus.51004&rft_dat=%3Cproquest_pubme%3E2917863403%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2920609823&rft_id=info:pmid/38259389&rfr_iscdi=true |